ReviewOpen respiratory archives
Therapeutic Bronchoscopic Intratumoral Injection in Lung Cancer: Current Advances, Challenges, and Opportunities for Resource-Limited Settings.
Review in Open respiratory archives. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the leading cause of cancer-related deaths globally, with a high burden in Southeast Asia, including Indonesia. Conventional treatments, including surgery, radiotherapy, and systemic chemotherapy, are often limited by patient factors such as multifocal disease, poor pulmonary reserve, or central airway obstruction. This review explores bronchoscopic intratumoral injection as a novel, localized therapeutic strategy and assesses its feasibility in resource-limited settings. We conducted a narrative synthesis of recent literature on bronchoscopic intratumoral injection techniques, therapeutic agents, clinical outcomes, and implementation challenges. Additional focus was placed on the Indonesian healthcare context, particularly the infrastructure in West Sumatra. Bronchoscopic intratumoral injection delivers chemotherapeutic, immunologic, or gene-based agents directly into tumors using flexible bronchoscopy, including transbronchial needle injection, endobronchial ultrasound-guided injection, and cone-beam computed tomography. This approach achieves high local drug concentrations with minimal systemic toxicity, shifting the paradigm toward immune modulation and durable tumor control. Clinical outcomes include improved airway patency, lung function, symptom relief, and survival in patients ineligible for standard therapies. Feasibility in Indonesia is supported by existing clinical resources and agent availability. Despite challenges, such as limited access to advanced imaging, specialized equipment, and skilled personnel, bronchoscopic intratumoral injection may represent a promising investigational strategy in selected cases. Further research is warranted before routine clinical implementation can be contemplated. Strategies such as structured training and regional collaboration can bridge implementation gaps, aligning innovation with equitable lung cancer care in developing countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.